Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Syndrome

Thrombosis

Polycystic Ovary Syndrome

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Hypoglycemic Agents

Gastrointestinal Agents

Glucagon-Like Peptide 1

Liraglutide

Glucagon

Glucagon-Like Peptide-1 Receptor Agonists

Incretins

Hormones

Hormone Antagonists

Liraglutide s.c. 1,8mg daily for 26 weeks

GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks

Liraglutide for 26 weeks

placebo

Jens Faber, DSc

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS.

70 women will be included in af RCT.

Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

LIPT - Liraglutide in Polycystic Ovary Syndrome

A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

Ration between number of bleedings during 3 months before trial and last 3 months of trial

Area under curve in a Thrombin Generation Test (TGT). Measurements every min for 10 min

Jens Faber

Professor, DSc, Senior Hospital Physician

Liraglutide s.c. 1,8mg daily for 26 weeks

Liraglutide: GLP-1-analogue Liraglutide

Active

Placebo s.c. 1,8mg daily for 26 weeks

placebo

Placebo

Total

Age, Continuous

women

Sex/Gender, Customized

caucasians

other ethnicity

Race/Ethnicity, Customized

Waist Circumference

Total testosterone

Endogenous Thrombin Potential

Professor Jens Faber

Change in Endogenous Thrombin Potential (ETP)

Percent Change in Plasma Level of Plasminogen Activator Inhibitor -1 PAI-1

Change in Plasma Level of Adrenomedullin

Change in Plasma Level of Atrial Natriuretic Peptide (ANP)

Change in Plasma Level of Copeptin

Percent Change in Plasma Level of High Sensitivity C-reactive Protein (CRP)

Change in Bleeding Pattern (Bleeding Ratio)

only participants with measurable i.e. \>5% liver fat at baseline was included in this analysis

Change in Percent Liver Fat Content

not measured on all subjects (missing. 4 in Liraglutide and one in placebo Group)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
LIPT - Liraglutide in Polycystic Ovary Syndrome	NCT02073929	Polycystic Ovar... Cardiovascular ...	Liraglutide for... placebo	18 Years - 60 Years	Herlev Hospital
LIPT - Liraglutide in Polycystic Ovary Syndrome	NCT02073929	Polycystic Ovar... Cardiovascular ...	Liraglutide for... placebo	18 Years - 60 Years	Herlev Hospital

Spots Global Cancer Trial Database for liraglutide for 26 weeks